论文部分内容阅读
作者采用M2方案治疗33例分泌型多发性骨髓瘤(MM)复治患者,均为马法兰和类固醇激素耐药或M2方案治疗后复发的病例。耐药组20例,复发组13例。 M2方案:长春新碱0.03mg/kg、环磷酰胺10mg/kg和卡氮芥0.5mg/kg,静注第1天;马法兰0.25mg/kg,口服,第1-4天;强的松1mg/kg,口服,第1-7天和0.5mg/kg,第8-15天,间隔21天重复,如骨髓抑制治疗顺延至骨髓恢复;白细胞<2.5×10~9/L和血小板<100×10~9/L,马法兰减少为0.16mg/kg。根据M蛋白量计算肿瘤细胞数。肿瘤细胞量或血清/尿中M蛋白量减少>50%为显效,减少30%-50%为改善,<30%为无效。有效期从M蛋白少于初值的70%时至上升达缓解期最低值2倍
The authors used M2 regimen in the treatment of 33 patients with secretory multiple myeloma (MM) retreatment, both with melphalan and steroid hormone resistance or M2 regimen after treatment recurrence. Drug-resistant group of 20 cases, 13 cases of recurrence group. M2 regimen: vincristine 0.03 mg / kg, cyclophosphamide 10 mg / kg and carmustine 0.5 mg / kg on day 1 of intravenous injection; melphalan 0.25 mg / kg orally, day 1-4; prednisone 1 mg / kg, orally, 1-7 days and 0.5mg / kg, 8-15 days, 21 days intervals, such as bone marrow suppression therapy extended to bone marrow recovery; white blood cells <2.5 × 10 ~ 9 / L and platelets <100 × 10 ~ 9 / L, melphalin reduced to 0.16mg / kg. The number of tumor cells was calculated from the amount of M protein. Tumor cell mass or serum / urine M protein was reduced> 50% markedly, a 30% -50% reduction was improved, <30% was invalid. Valid from less than 70% of the initial value of the M protein to 2 times the minimum ascending remission